Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Merck and Daiichi Sankyo, which were seeking approval of patritumab deruxtecan for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...

Merck & Co Inc. (MRK) and Daiichi Sankyo on Thursday said that the companies have withdrawn their application to the U.S.